Printer Friendly

Red-yeast product is no drug, court says.

In a setback for the Food and Drug Administration, a federal district court ruled last week that the agency had unlawfully attempted to restrict an herbal supplement as a prescription drug.

Pharmanex of Simi Valley, Calif., began marketing capsules of rice fermented with a red yeast in November 1996. Almost immediately, FDA ordered the company to stop selling the cholesterol-lowering product, sold as Cholestin, charging that it is a drug. Studies had shown that the fermented rice contains a natural compound that is chemically indistinguishable from lovastatin, the active ingredient in a cholesterol-lowering prescription drug (SN: 11/14/98, p. 311).

Pharmanex fought the drug designation for its over-the-counter product, however, citing a 1994 law known as the Dietary Supplement Health and Education Act (DSHEA). When FDA countered by ordering the company to stop importing its bulk fermented rice from China, Pharmanex sued in what became the first legal test of DSHEA.

Last June, pending a thorough study of the case, Judge Dale A. Kimball of the Federal District Court in Salt Lake City restrained FDA from imposing its ban on the Chinese rice. Kimball's final decision now decrees that Cholestin indeed is a food as defined by DSHEA.

The judge noted that Congress, in explaining a clause in the legislation, had acknowledged, "On occasion, a substance that is properly included as a dietary ingredient in a dietary supplement (food) product may also function as an active ingredient in a drug." That's the case here, Kimball said.

For now, FDA is "reviewing the court's decision and evaluating what steps we might take," says Brad Stone, a spokesman in Rockville, Md.
COPYRIGHT 1999 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Pharmanex wins case over FDA
Author:Raloff, J.
Publication:Science News
Article Type:Brief Article
Geographic Code:1USA
Date:Feb 27, 1999
Words:270
Previous Article:Teasing Out a Tongue's Taste Receptors.
Next Article:Fickle climate thwarts future forecasts.
Topics:


Related Articles
Supplements supply dietary danger, as FDA looks on.
The role of FDA approval in drug cases.
Manufacturers may promote off-label uses for drugs.
FDA ADVISORY PANEL BACKS NEW AMGEN DRUG.
New Cox-2 pain relievers are marketing marvel, not miracle drugs.
Lawsuits fault off-label use of Neurontin in suicide cases.
A cure worse than the disease: recent FDA actions and newly disclosed research on the link between antidepressants and suicide - especially among...
Taking on big pharma - and the FDA: the fight against federal preemption is far from over, but some courts have rejected drug company claims that an...
Focus on facts to defeat preemption: while preemption is primarily a question of law, factual evidence about a federal agency's action or inaction...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters